Presentation Type
Poster
Discipline Track
Biomedical Science
Abstract Type
Research/Clinical
Abstract
Pancreatic adenocarcinoma (PDAC) has a very poor survival rate due to late diagnosis. Therefore, identification approaches that aid in early diagnosis are highly desirable. MUC13 is a recently identified high molecular weight glycoprotein that is aberrantly expressed in PDAC and allows its progression via alterations of multiple tumor signaling pathways. Overexpression of MUC13 in PDAC cells leads to enhanced tumorigenic and metastatic phenotypes. These characteristics of PDAC cells are mediated by physical interactions between MUC13 and HER2/Neu. This study elucidates significance of MUC13, as a diagnostic and imaging marker of PDAC. Additionally, a collaborative effort has commenced to investigate the targeting ability of a novel anti-MUC13 monoclonal antibody (MAb) “C14” by radiolabeling with 89Zr for in vivo microPET/CT imaging.
Academic/Professional Position
Faculty
Mentor/PI Department
Immunology and Microbiology
Recommended Citation
Khan, Sheema and Dhasmana, Anupam, "MUC13- A Novel Cancer Biomarker for Early Pancreatic Cancer Diagnosis and Imaging" (2024). Research Symposium. 88.
https://scholarworks.utrgv.edu/somrs/2024/posters/88
Included in
MUC13- A Novel Cancer Biomarker for Early Pancreatic Cancer Diagnosis and Imaging
Pancreatic adenocarcinoma (PDAC) has a very poor survival rate due to late diagnosis. Therefore, identification approaches that aid in early diagnosis are highly desirable. MUC13 is a recently identified high molecular weight glycoprotein that is aberrantly expressed in PDAC and allows its progression via alterations of multiple tumor signaling pathways. Overexpression of MUC13 in PDAC cells leads to enhanced tumorigenic and metastatic phenotypes. These characteristics of PDAC cells are mediated by physical interactions between MUC13 and HER2/Neu. This study elucidates significance of MUC13, as a diagnostic and imaging marker of PDAC. Additionally, a collaborative effort has commenced to investigate the targeting ability of a novel anti-MUC13 monoclonal antibody (MAb) “C14” by radiolabeling with 89Zr for in vivo microPET/CT imaging.